Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the
            US
            community oncology setting

Triple-negative breast cancer (TNBC) comprises 12–20 % of all breast cancers. TNBC is defined by the absence of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) expression. TNBC is a heterogeneous disease, with an aggressive clinical feature, a higher risk of both local and distant visceral and / or brain metastases. Recurrence usually develops between 1 and 3 years after the initial diagnosis and most deaths occur within 5 years. Epidemiologic studies illustrate a high prevalence of triple-negative breast cancers among young women. Triple-negative breast cancer is also more likely to occur in women that carry a BRCA mutation, especially if they are diagnosed at a young age. Cytotoxic chemotherapy remains the mainstay treatment for TNBC because there are currently no specific targets for treatment options (hormone receptors or HER-2 amplification). Chemotherapy combined with targeted agents including DNA repair with PARP inhibitors, EGFR inhibitors, anti-angiogenic agents and a Chk1 inhibitor produced modest improvement in response rate and overall survival. Nevertheless there’s no common standards for treatment such patients with metastatic TNBC. Progress in the development of new regimens and combination of drug treatment agents for patient with generalized TNBC remains an important challenge that could lead to improvement immediate and long-term outcomes.

Download Full-text

Faculty Opinions recommendation of Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735554384.793559073 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Eribulin Mesylate ◽

Phase 1B

Download Full-text

The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients

PLoS ONE ◽

10.1371/journal.pone.0143061 ◽

2015 ◽

Vol 10 (11) ◽

pp. e0143061 ◽

Cited By ~ 39

Author(s):

Weijuan Jia ◽

Jiannan Wu ◽

Haixia Jia ◽

Yaping Yang ◽

Xiaolan Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Blood Neutrophil ◽

Breast Cancer Patients ◽

Term Survival ◽

Peripheral Blood Neutrophil ◽

Lymphocyte To Monocyte Ratio

Download Full-text

Long-term survival of a patient with relapsing triple-negative breast cancer stage IIB under surgical treatment and Viscum album extracts – A case report

Phytomedicine ◽

10.1016/j.phymed.2019.09.095 ◽

2019 ◽

Vol 61 ◽

pp. 9

Author(s):

Paul Georg Werthmann ◽

Angela Kuck ◽

Gunver S. Kienle

Keyword(s):

Breast Cancer ◽

Case Report ◽

Surgical Treatment ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Viscum Album ◽

Cancer Stage ◽

Term Survival ◽

Long Term Survival

Download Full-text

Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai

JCO Global Oncology ◽

10.1200/go.21.00001 ◽

2021 ◽

pp. 767-781

Author(s):

Manikandan Dhanushkodi ◽

Velusamy Sridevi ◽

Viswanathan Shanta ◽

Ranganathan Rama ◽

Rajaraman Swaminathan ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Neoadjuvant Chemotherapy ◽

Triple Negative Breast Cancer ◽

Tumor Size ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced

PURPOSE There are sparse data on the outcome of patients with locally advanced breast cancer (LABC). This report is on the prognostic factors and long-term outcome from Cancer Institute, Chennai. METHODS This is an analysis of untreated patients with LABC (stages IIIA-C) who were treated from January 2006 to December 2013. RESULTS Of the 4,577 patients with breast cancer who were treated, 2,137 patients (47%) with LABC were included for analysis. The median follow-up was 75 months (range, 1-170 months), and 2.3% (n = 49) were lost to follow-up at 5 years. The initial treatment was neoadjuvant concurrent chemoradiation (NACR) (77%), neoadjuvant chemotherapy (15%), or others (8%). Patients with triple-negative breast cancer had a pathologic complete response (PCR) of 41%. The 10-year overall survival was for stage IIIA (65.1%), stage IIIB (41.2%), and stage IIIC (26.7%). Recurrence of cancer was observed in 27% of patients (local 13% and distant 87%). Multivariate analysis showed that patients with a tumor size > 10 cm (hazard ratio [HR], 2.19; 95% CI, 1.62 to 2.98; P = .001), hormone receptor negativity (HR, 1.45; 95% CI, 1.22 to 1.72; P = .001), treatment modality (neoadjuvant chemotherapy, HR, 0.56; 95% CI, 0.43 to 0.73; P = .001), lack of PCR (HR, 2.36; 95% CI, 1.85 to 3.02; P = .001), and the presence of lymphovascular invasion (HR, 1.97; 95% CI, 1.60 to 2.44; P = .001) had decreased overall survival. CONCLUSION NACR was feasible in inoperable LABC and gave satisfactory long-term survival. PCR was significantly higher in patients with triple-negative breast cancer. The tumor size > 10 cm was significantly associated with inferior survival. However, this report acknowledges the limitations inherent in experience of management of LABC from a single center.

Download Full-text